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Attitudes of intravenous drug users in London towards 
the provision of drug consumption rooms  
Abstract 
Aims:  The study investigated the attitudes of intravenous drug users (IDUs) towards the 
provision of drug consumption rooms (DCRs) in the UK and their willingness to use DCRs. 
Methods: Participants were 90 methadone-maintained outpatients recruited from a London 
clinic. A questionnaire asked about their willingness to use a DCR, their views on various 
rules commonly-implemented by DCRs, and how they believed DCRs might impact on the 
drug-taking behaviours of drug users and their peers. Findings: A large majority (89%) 
expressed willingness to use a DCR and accepted the need for rules such as no drug sharing 
(84.3%), no assistance with injecting (81.8%), compulsory supervision (76.7%) and 
compulsory hand washing (92.1%). However, the IDUs were split over whether injection in 
the neck or groin should be disallowed and whether certain categories of IDUs (e.g. juveniles, 
pregnant women) should be excluded from DCRs. Majorities thought it unlikely that DCRs 
would encourage users to try risker drug preparations (76.6%), or encourage non injectors to 
inject for the first time (74.5%). Conclusions: In a country where DCRs are not available, the 
study highlights the willingness of IDUs to use a DCR and accept its rules, even for a sample 
most of whom were not homeless.  
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Attitudes of intravenous drug users in London towards the provision of drug consumption 
rooms. 
 
Introduction 
Some of the most significant problems associated with drug abuse are a consequence of the 
use of parenteral routes of administration, in particular the intravenous injection of drugs 
(EMCDDA, 2012). Intravenous administration is common amongst heroin users, for whom 
the profile of drug use is often long term and involves periods of abstinence and relapse 
(McLellan, 2000: Hser et al., 2001). Frequent relapse to injecting drug use also occurs during 
methadone maintenance treatment (Termorshuizen et al., 2005; Gossop et al., 2003).   
Injecting drugs creates a host of potential problems for the user (Kerr et al., 2006; Hunt, 
2006); it also impacts substantially on the wider community in a number of ways (Kerr et al., 
2006; Cusick & Kimber, 2007). For example, tens of thousands of drug injections occur in 
public places in England every month (IWG, 2006) and this is not exclusively by homeless 
users.  A report ten years ago (IWG, 2006) indicated that 25% of those living in their own 
accommodation had injected in a public place in the previous week. Injecting in public places 
is associated with drug-dealing and the discarding of needles and other drug paraphernalia; 
these behaviours inevitably create concern among the affected communities (Cusick & 
Kimber, 2006). Importantly, for the user, injecting in public places is also associated with an 
increased risk of needle-sharing, HCV infection and overdose (Latkin et al., 1994).   
In adopting public health policies centered on harm reduction, some countries have 
introduced drug consumption rooms (DCRs; also known as safe injection facilities (SIFs) or 
medically supervised injecting centers (MSICs) for injecting drug users (IDUs)). These 
include eight European Countries, where there are 88 DCRs (Woods et al, 2014), and one in 
each of Australia and Canada.  DCRs operate in cities near to drug markets and are legally-
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sanctioned, supervised places where IDUs can inject street-bought drugs in a clean and safe 
environment. Sterile injecting equipment and safe disposal facilities are provided and staff 
are available to deal with overdoses or other emergencies (Hedrich, 2004; Dolan et al., 2000). 
The IDUs may also receive referrals to other services, such as drug treatment programmes. 
The primary aims of DCRs are to reduce the harms associated with unsupervised injection, 
such as overdose and syringe sharing (Kerr et al., 2005), and to improve health outcomes for 
IDUs such as reduced risk of HIV infection (Pinkerton, 2010). They may also have ancillary 
benefits to the local community, such as reducing drug- related litter (IWG, 2006; KPMG; 
2010; Wood et al., 2004).  All DCRs have explicit rules with which the users must comply, 
such as no sharing of drugs, and no injecting in the neck or groin (Hedrich, 2004). Particular 
entry criteria may also be adopted, for example regular use of heroin or cocaine, and the 
exclusion of anyone under 18 years old. Non-injecting drug users who want to conduct their 
first injection at a DCR are also typically excluded (Hedrich, 2004). 
At present there are no such facilities in the UK. A report by An Independent 
Working Group, commissioned by The Joseph Rowntree  Foundation (a  UK charity working 
for social change),   included  reviewing evidence on DCRs in other countries, 
commissioning research on DCRs, visiting DCRs, and conducting consultations with drug 
users.  After the 20 month review period, it recommended that DCRs be piloted in the UK 
(IWG, 2006). However, specific ethical concerns were raised by the IWG, in particular that 
the provision of DCRs might serve to encourage non-injectors or partners of IDUs to inject 
for the first time, or they might provide a sense of security that could encourage IDUs to try 
more risky drug taking practices. The IWG recommended that piloting schemes and 
evaluation could address these concerns. However, pilot schemes have not been trialled in the 
UK since the report and neither has any research been undertaken to investigate the ethical 
issues raised.The UK government rejected the IWG recommendations, primarily due to  a 
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perceived lack of evaluation of DCRs, legal complications (potential conflict with  UN 
conventions or the Misuse of  Drugs Act), concerns about how the public would react, the 
cost  of implementation, and the possibility that DCRs might attract drug dealers to an area  
(Lloyd & Hunt, 2007). Many of these are indeed contentious issues, but Lloyd and Hunt 
(2007) have previously argued that government objections to DCRs in 2002 and 2007 carried 
little weight. Lloyd (2016; as cited in Broe, 2016) noted that in the UK there is a lack of 
political will for DCRs.  
Nevertheless, there are some evaluation data from a number of countries that have set 
up DCRs. A ten year evaluation of a DCR in Sydney, Australia, reported a decrease in drug 
overdose deaths: despite a large number of overdoses occurring in the DCR, there had not 
been a single death onsite. Reduced sightings of injecting and discarded needles/syringes by 
local residents and businesses were also reported (KPMG, 2010).  A number of evaluations of  
the DCR provision in Vancouver, Canada, also showed positive outcomes, including cleaner 
injecting practices, reduced injecting in public places, less unsafe syringe disposal and 
reduced needle sharing  (Wood et al., 2004; Petrar et al., 2007). In addition, the facility 
attracted higher-risk IDUs including public injectors and users at high risk for HIV and 
overdose (Wood et al., 2005). A review of the literature on DCRs reported that DCRs were 
successful in several respects, for example by attracting the most marginalized IDUs, 
facilitating access to health care, and reducing overdoses; these were achieved without an 
increase in intravenous drug use or criminal activity (Potier, et al., 2014). 
The Sydney MSIC evaluation (MSIC, 2003) highlighted a large number of overdoses 
at the centre and suggested that these may reflect the adoption of riskier drug taking practices 
(such as using more heroin). However, a Europe-wide report on DCRs found no evidence that 
such facilities “increase levels of drug use or encourage riskier patterns of use, nor that they 
increase morbidity and mortality” (Hedrich, 2004; p79). It also concluded that “there is no 
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evidence that consumption rooms encourage increased drug use or initiate new users” 
(Hedrich, p 84). Further research is needed to examine how drug taking practices change in 
DCRs, whether they help to initiate non-injectors into injecting as well as issues such as their 
cost-effectiveness and the likely uptake and acceptability of such facilities in the UK.  
Previous studies assessing the likelihood of using a DCR have generally reported 
willingness to use such a facility. In Sydney, 66% of IDUs who last injected in a private place 
and 83% who last injected in a public place reported being willing to use a DCR (van Beek & 
Gilmore, 2000). Similarly, in Montreal, Canada, 76% of IDUs who injected in public or 
semi-public places reported willingness to use a DCR if it was established (Green, Hankins, 
Palmer, Bovin & Platt, 2004). Fry (2002) found that the majority (89%) of IDUs interviewed 
(in Melbourne, Australia) would be willing to use a DCR if it was near to where they 
purchase and use drugs. Large majorities also reported willingness to use a DCR even if rules 
were implemented, such as hand washing prior to injecting, no assisting of others to inject, 
and supervision by staff. In Vancouver, 92% of the sample reported being willing to use a 
DCR (Kerr, Wood, Small, Palepu & Tyndall, 2003). However, looking specifically at IDUs 
who had injected during the previous month, Wood et al. (2003) found that only 36.6% were 
willing to use a DCR. DeBeck, et al. (2012) examined whether an initial willingness to use a 
DCR in Vancouver, prior to its opening, was associated with actual use of the facility 
subsequently. Of those who had claimed to be willing to use the facility before it opened, 
72% reported attending the facility; moreover, 54% of those who had reported being 
unwilling to use the DCR also reported attending. Willingness to attend predicted later 
attendance even after adjusting for other factors associated with willingness (e.g. age, gender, 
daily drug use, injecting in public locations). In the UK, Hunt, Lloyd, Kimber and Tompkins 
(2007) examined willingness to use a DCR in a sample of IDUs, most of whom were living in 
insecure housing and reported injecting in the previous week. The proportion willing to use a DCR if 
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available (84%) was similar to that reported by Kerr et al (2003). They also reported a greater 
willingness to use a DCR by users who routinely injected in public (although public injecting was also 
seen in those who lived in secure housing).   
Whilst IDUs in other countries generally report in favour of DCRs there are a number of 
barriers to the opening of DCRs; these include political and legal issues and public resistance. Lissen 
et al.( 2001, as cited in Hedrich, 2004) noted that while DCRs in the Netherlands had a  positive effect 
on public nuisance there was no effect on nuisance caused by drug dealing and general neighbourhood 
degeneration. Woods (2014) notes that at the time of set up, neighbours of DCRs in Europe showed 
more resistance to the facility than once it is established. The public’s concerns often centre on the 
potential to attract drug dealers and drug users to the area. However, Hedrich (2004) argued that these 
concerns are largely unsubstantiated: as DCRs operate close to drug markets, some drug dealing has 
inevitably been reported near to them (Hedrich, 2004). The success of DCRs in reducing public 
nuisance is largely dependent on their opening hours, capacity and location (Hedrich et al, 2010); 
most have to deal with queues (Woods, 2014).  
While there have been studies evaluating DCRs in Vancouver, Canada and Sydney, 
Australia and some studies investigating IDUs’ attitudes and willingness to use DCRs in 
areas where DCRs were being considered or were about to be implemented, there has been 
limited research into the attitudes of IDUs towards DCRs in a country such as the UK where 
there are no DCRs at present and none planned in the foreseeable future. Furthermore, studies 
have mainly solicited views about DCRs from homeless IDUs or from those in insecure 
housing, or IDUs who are considered to be most at risk. The current study is novel as it 
examined the views of current and past IDUs, most whom were not homeless and lived in 
secure housing. The current study included IDUs who were not currently injecting as well as 
current injectors as a number of IDUs who have ceased injecting have been reported to 
relapse into injecting drug use, with longitudinal studies showing estimates of only 20-50% 
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of injecting drug users (IDUs) who were drug free at follow up (Hser et al, 2001; Galai et al, 
2003).  
The aims of the present study were to survey the attitudes of IDUs in London (UK) to 
DCRs and to build on the findings of the IWG (2006). The study was not designed with any a 
priori view about promoting or arguing against DCRs or as a means to directly address the 
political argument surrounding DCR implementation in the UK. The study focused on three 
key aspects: IDUs’ willingness to use such facilities if they were available; how such 
willingness might be affected by specific DCR rules; and beliefs about how DCRs might 
impact on drug-injecting by oneself or others. For the third aspect, three specific ethical 
concerns about DCRs were considered: whether they would encourage non-injectors to 
inject; whether they would lead to the use of more drug or riskier practices; and whether they 
might encourage partners/friends to inject. These three ethical concerns have been identified 
by the independent working group (IWG, 2006) as important ethical issues deserving further 
investigation.  
 
Methods 
Participants 
Participants were 90 intravenous drug users (IDUs) who attended a centre in London that 
provided methadone treatment, needle exchange, medical help and a range of advice services 
along with a drop-in service for dependent drug users. The centre was approached by the 
second author (DC) who was working as a volunteer. Participants were current or past 
injectors of at least one illicit drug and were all receiving methadone; they were approached 
in the methadone dispensary clinic during clinic hours, informed about the study and invited 
to take part; all of those who took part gave informed consent. Most participants (N=62, or 
69%) were male with a mean age of 39.3 years (range 23-55 years); the mean age of the 28 
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females was 37.3 years (range 21-58 years). Ninety-four per cent were white British, 2% 
were black British, 3% were other white race and data on ethnicity were missing for one 
participant.  Eighty-four per cent were unemployed and 30.7% were homeless. Only 
participants who did not exhibit overt signs of intoxication at the point of invitation were 
invited to take part. After participation they were provided with a voucher that could be 
exchanged for food in the cafeteria  
 
Materials and Procedure 
A 34-item questionnaire was designed for the study. The questions were informed by rules 
that commonly apply to DCR schemes in other countries and by previous research (e.g. van 
Beek & Gilmore, 2000; Fry, 2002) and by concerns raised by the IWG (2006). The 
questionnaire assessed knowledge about DCRs (e.g. “What do you think a drug consumption 
room is?”), willingness to use a DCR, attitudes about rules commonly applied in DCRs, and 
beliefs about the impacts of DCRs on drug user behaviour. It also covered socio-demographic 
information and drug use history, including questions about injecting in public and private 
places, sharing of equipment, needle disposal practices and experiences of overdose. Eighteen 
questions required simple “yes” or “no” answers, and for thirteen of these questions - 
specifically relating to the various rules commonly implemented in DCRs - the participants 
were asked to provide reasons for their answers. Three other questions addressed important 
ethical concerns relating to the consequences of DCR provision, namely: (1) The possibility 
that DCRs would encourage non-injecting drug users to inject for the first time; (2) The 
possibility that DCRs would encourage IDUs to use higher drug doses, riskier preparations or 
riskier drug combinations than they would otherwise use; (3) The possibility that DCRs 
would encourage non-injecting partners/friends of IDUs to inject. Participants responded to 
each of these three questions by checking one of four boxes, labelled: “very high”, “quite 
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high”, “quite low” or “very low”. Issues of data confidentiality, participant anonymity and the 
right to withdraw were strongly emphasised, and it was made clear that participation or not 
would have no bearing on their relationship with the centre in any way. Participation took 
approximately 30 minutes. Participants were assisted with filling in the questionnaire where 
there were literacy problems. The study was approved by the Research Ethics Committee of 
Kingston University Faculty of Arts and Social Sciences and also by the centre from which 
participants were recruited.  
 
Results 
Not all participants responded to every question, therefore the results are often expressed as 
percentages of the numbers who responded and of subsets who responded in particular ways.  
Drug use characteristics of participants   
At the time of participation, 68% (N=61) of the sample were still injecting drugs; 38% of 
these 61 reported injecting every day. Of the 32% (N=29) of the sample who were not 
currently injecting, 6 had injected in the previous twelve months, and the remaining 23 had a 
history of intravenous drug use prior to that. The most commonly injected drug was heroin 
(identified by 82.2% of 74 respondents), followed by cocaine (20% of 71 respondents), then 
amphetamine (8.9% of 68 respondents). Seventy-seven participants provided information 
about the length of time that they had been injecting. The durations ranged from six months 
to 41 years (mean = 16.5 years, SD = 9.5 years). A substantial majority of those who 
responded had injected for more than 5 years (85.7%); indeed, many had injected for over 20 
years (41.6%). Of the 66 participants who responded to a question asking about their normal 
methods of needle disposal, 73% reported using only a needle exchange programme, with 
another 3% using both needle exchange and litter bins. However, 20% disposed of injection 
equipment in litter bins or tins only; the remaining 5% used a sharps bin. Data from 66 
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participants indicated that 77% injected primarily in private locations whereas 23% injected 
in private or public places. However, despite the widespread preference to inject in a private 
place, 46% (of 68 respondents) reported having injected in a public place at least once in the 
previous month. 
 
Knowledge of DCRs and willingness to use them  
To determine whether the IDUs understood what was meant by a drug consumption room 
they were asked: “What do you think a drug consumption room is? (Also known as a safe 
injecting facility)”. Most participants responded to this question (N = 87); of these, 85% 
claimed to be familiar with the idea of DCRs. Of the participants who knew about DCRs, 
81% identified DCRs as safe environments in which to inject drugs, 12% simply reported 
them as places to inject. DCRs were described as “not a good idea” by 4% and as “a drug den 
by 3%. After clarifying what participants understood by a DCR, 77 out of 87 (i.e. 89%) 
indicated that they would be willing to use a DCR. Of the 61 participants who were still 
injecting at the time of data collection 95% indicated that they would be willing to use a 
DCR, whereas 73% of the 26 participants who were no longer injecting declared a 
willingness to use a DCR (χ2 (1) = 8.68,  N = 87, p = .003). There was an overwhelming 
preference expressed for injecting in a DCR over a public place: 83 of 88 participants who 
responded (94%). However, only 26.7% (24 of the 88) reported that they would prefer to 
inject in a DCR rather than in a private place.   
 
Attitudes towards rules applied by DCRs 
Substantial majorities of participants stated that they would be willing to use DCRs with the 
most common rules that currently operate in most DCRs: Compulsory handwashing (92.1% 
of 89 respondents); No help with injecting (81.8% of 90 respondents); Compulsory 
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supervision (76.7% of 90 respondents). A large majority, 84.3% (out of 89 respondents), 
were also willing to use a DCR if drug sharing was not permitted, albeit that 5 of 45 
respondents (11.1%) who gave a reason said that they would split/share drugs before 
entering the facility. Participants were also asked if users of the DCR should not be allowed 
to inject in the neck or groin: of the 85 participants who responded to the question, 71.8% 
(61) disagreed with the rule.  Of the 61 participants who disagreed, 70.5% gave as their 
reason the fact that the neck and groin were the only places left to inject for some IDUs.  
 
Finally, participants were asked if certain categories of IDUs should be not allowed to use a 
DCR and whether or not health checks should be compulsory for users. Table 1 shows  that 
there was support for access by novice users and non-residents, as only a minority agreed 
these groups should not be allowed access to the DCR, but the sample was split over 
allowing access to people under the age of 18 years old or to pregnant women. Participants 
(N = 88 respondents) were also quite evenly divided over the issue of compulsory health 
checks for access to facilities: 46 (52.3%) agreed and 42 (46.7%) disagreed.  
 
----- TABLE 1 APPROXIMATELY HERE ---- 
 
Views on ethical concerns expressed about the impacts of DCRs 
For each of the three ethical concerns, analyses were conducted to compare the views of the 
61 current IDUs and the 29 participants who were not currently injecting. There were no 
statistically significant differences between the two groups on any of the three issues, hence 
their results will be considered together.  
 
1. Will DCRs encourage injecting by non-injectors? Participants were asked if they thought 
that DCRs would attract non-injectors to inject for the first time, taking into account that 
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DCRs would not allow assistance with injecting. Only about one-quarter thought it probable 
(10% rated the possibility as “very high”, 15.6% rated it “quite high”); whereas nearly three-
quarters thought it unlikely (35.6% rated the possibility “quite low” and 38.9% “very low”).  
2. Will DCRs encourage riskier drug use by injectors? The issue of whether DCRs might 
encourage users to take greater quantities of drugs or to use more risky preparations or 
combinations was assessed. The split in views was similar to the previous question: the 
likelihood was rated as “very high” by 10%, “quite high” by 13.3 %; “quite low” by 42.2% 
and “very low” by 34.4%. 
3. Will DCRs encourage non-injecting partners/friends to inject? Participants were asked 
whether non-injecting partners/friends of IDUs might be tempted to inject in a DCR if 
available. Here, the sample was more evenly divided between those who agreed and those 
who disagreed: 14.4 % rated the likelihood as “very high”, 28.9 % as “quite high”, 32.2 % as 
“quite low” and 24.4% as “very low.  
 
Discussion 
The study found that the majority of IDUs knew what a DCR was and indicated a willingness 
to use a DCR if one was established. The high level of willingness to use a DCR is consistent 
with the findings of Hunt et al. (2007), also with a UK sample, as well as with findings from 
other countries (van Beek & Gilmore, 2000; Green et al., 2004;  Fry, 2002;  Kerr et al., 2003; 
DeBeck et al., 2012). A significantly higher proportion of current IDUs expressed willingness 
to use DCRs than those who were not currently injecting, although the question did not ask 
them to reflect on their view as if they were still injecting. The majority of participants also 
stated that they were willing to use DCRs if rules were implemented, including no assistance 
with injecting. The majority of IDUs also showed willingness to use a DCR if handwashing 
was compulsory and if supervision was compulsory. Very few IDUs expressed concerns 
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about prohibiting drug sharing/splitting at the DCR, although a small proportion admitted that 
they were likely to split their drugs before entering the DCR. Kerr et al (2003) found that 
over 60% were willing to use DCRs even if drug sharing and assisted injection were 
prohibited; similarly, Kral et al. (2010) reported that 67% of IDUs would accept a rule that 
drug sharing is not allowed . Fry (2002) found that IDUs were willing to use a DCR if they 
were prevented from assisting others to inject, as long as the DCR was close to where the 
user purchased and used drugs. Fry (2002) also found that just over half were still willing to 
use a DCR if they were prevented from splitting drugs on the premises, a lower proportion 
than in the current study. Overall, the current study, of past and present IDUs in the UK, 
indicates similar levels of willingness to use DCRs under similar rules as in other countries.  
This lends support to the view that DCRs might yield similar benefits in the UK.  
Where IDUs showed disagreement with probable DCR rules was in relation to the 
prohibition of injection in the neck or groin. Most participants (72 %) disagreed with this 
rule, the main reason being that for some users these were the only places left to inject. This 
result may reflect the fact that whilst some users are forced to inject in the neck and groin as a 
result of long-term injecting, it has become increasingly normal in some English cities 
(Rhodes et al., 2006). Maliphant and Scott (2005) reported that 51% of their UK sample of 
IDUs was injecting in the groin because no other convenient sites were considered to be 
accessible and the likelihood of heroin users injecting into sites other than the arm increases 
with the duration of injecting (Karimi et al., 2014). Therefore this is an issue which will need 
addressing by all DCRs as many target long term and problematic injectors and prohibit 
injecting into the neck and groin.  
IDUs in the current study were asked whether they agreed that certain people should 
not be allowed to use a DCR. Around three-quarters disagreed with a rule that novice 
injectors and non-residents should not be allowed to use a DCR. The proportion that felt non-
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residents should not be able to use a DCR, around one quarter, is lower than among a sample 
of IDUs in San Francisco, USA, where 34% agreed that users of a DCR should live in the 
neighbourhood (Kral et al., 2010). The difference between these two samples, London and 
San Francisco, may be due to the higher number of homeless people in the San Francisco 
sample, where the majority was homeless. In contrast nearly half in the current study agreed 
that pregnant women should not be permitted to use a DCR and just over half agreed that 
those under 18 years should not be permitted to use a DCR. These attitudes against pregnant 
women or non-residents being allowed to access the facility are not in line with the findings 
from a stakeholder survey in Canada (Fisher & Allard, 2007). That study showed the majority 
of stakeholders thought that pregnant women should be permitted to use a DCR, and that 
there should be as few barriers as possible to using a DCR. Zadjow (2006) noted that, at the 
time of their study, Sydney was the only DCR which did not allow access for pregnant 
women.  There is clearly some difference of opinion as to who should be allowed to use a 
DCR.  The differences are likely to reflect location-specific factors concerning the 
composition of the local drug using community, levels of homelessness and broader 
national/local policies for managing the treatment of drug misuse. The findings indicate a 
need for dialog with the likely users of new facilities when developing regulations for access 
to the DCR; such regulations are likely to vary across locations. 
Although the majority of participants cited a private place as the usual place of 
injecting, 40% had nevertheless injected in a public place in the last month. Clearly, public 
injecting is not limited to the homeless and is not an exclusive choice by a subset of users, it 
is common amongst IDUs. It is important therefore that most participants in the current study 
reported a preference for using a DCR over a public place to inject. Similar outcomes were 
found in Canada and Australia (van Beek & Gilmore, 2000; Green et al., 2004). A report 
from a UK sample indicated that public injecting was associated with insecure housing (Hunt 
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et al., 2007), but in the current study only thirty percent of the sample was homeless and the 
majority lived in secure housing. Together, these results suggest that the majority of IDUs do 
not like to inject in public places but do so out of necessity due to a sense of urgency to inject 
and no other suitable place near to the drug market. Therefore DCRs are likely to reduce 
public injecting and to decrease the nuisance and litter associated with public injecting.  
The majority of participants felt that the probability of DCRs encouraging injecting by 
non-injectors was low. This may be because first-time injectors typically require assistance, 
and this is not permitted by most DCRs. Crofts et al.  (1996) reported that only 12% of IDUs 
injected themselves the first time; Kermode et al. (2007) reported that 94.5% of IDUs in their 
study were injected by someone else first time. They also found that the majority had helped 
someone else inject for the first time. Therefore the concern that DCRs would attract non-
injecting users to inject is not supported by the views of IDUs in this study and is consistent 
with previous research. A second ethical issue addressed was whether DCRs would 
encourage riskier drug use, such as taking greater quantities of drugs or riskier combinations 
or preparations. The likelihood was rated low by over three-quarters of participants, 
consistent with other reports that DCRs do not encourage riskier patterns of use (Hedrich, 
2004) and might in fact lead to less risky practices: the medically supervised injecting centre 
(MSIC, 2003) in Sydney found that almost half of the users of the centre reported less risky 
injecting practices since they began using the centre.  
The final ethical issue examined was whether DCRs would encourage non-injecting 
friends or partners of IDUs to inject. Participants were divided on this issue, with just over 
half rating the likelihood as low. If a person is thinking of injecting for the first time, then a 
medically supervised site may offer some sense of security if something goes wrong. 
However as most DCRs have rules which do not allow assistance with injecting and many 
first time injectors require or have assistance then this situation would be unlikely. 
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Furthermore the MSIC in Sydney has a policy of engaging with the non-injecting drug users 
who try to use the centre, assessing them and providing referral to services to discourage the 
transition to injecting (KPMG, 2010). Any DCR should be able to implement an analogous 
policy. Overall, these findings relating to the ethical concerns raised by the IWG suggest that 
the concerns are not supported by the evidence. 
There are a number of inevitable limitations with the current study.  For example,  it 
was reliant on self-report and there were no objective records available to verify details such 
as length of time injecting or if the participants were drug free at the point of data collection. 
However, other studies in settings where there is no client-health care provider relationship 
have found that self-reported drug use typically yields valid measures (Langendam et al., 
1999). Some caution is needed in comparing across studies. The composition of the sample in 
the present study was different from that in other studies which often include higher 
proportions of public injectors, at-risk IDUs and homeless people. The present sample also 
included people who were no longer injecting, and although they expressed less support for 
DCR use than current injectors, the findings for the sample as a whole were largely consistent 
with those reported elsewhere. Despite the sample differences, willingness to use DCRs was 
high and willingness to use if rules were in place was higher than in some other studies. The 
duration of injecting by IDUs was also consistent with other studies looking at long term 
IDUs. There were no significant differences between the views of those currently injecting 
compared to those who were not currently injecting on their attitudes regarding the three 
ethical concerns about DCRs. The views of those no longer injecting are important since, as 
experienced past injectors, they can provide a particular perspective on how DCRs might 
have impacted on their own trajectory towards abstinence; moreover, longitudinal studies 
suggest that significant numbers of abstinent drug users will relapse to injecting drug use 
(Galai et al, 2003; Hser et al, 2001) including those receiving methadone treatment (Gossop 
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et al, 2003: Termorshuizen et al, 2005).  A more recent consideration for those implementing 
new DCRs is the increase in the smoking of drugs (Hedrich et al., 2010). Although some 
established DCRs have booths for the smoking of drugs others do not and whether newly 
established DCRs would allow the smoking of crack or heroin or whether separate DCRs 
would operate for these groups of drug users, are all issues that would need to be considered 
as DCRs respond to changes in drug use.  
The findings have shed important light on the likely uptake of DCRs, and the 
implications are positive. Evaluations of DCRs in other countries have shown them to be 
cost-effective and to provide a range of benefits to IDUs and the communities in which they 
operate. Evaluation of such facilities prior to opening and also during and after a trial period 
would be necessary, in consultation with the appropriate stakeholders: users, service 
providers and local residents and businesses.  
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